No Benefit from Stem Cell Mobilization After Acute MI

Procedure is safe but does not improve heart function after stent placement

WEDNESDAY, March 15 (HealthDay News) -- Although it is safe to mobilize bone marrow stem cells with granulocyte-colony stimulating factor (G-CSF) injections after angioplasty for acute myocardial infarction (MI) it does not improve ventricular function, according to a study published online March 12 in Circulation: Journal of the American Heart Association.

Rasmus Sejersten Ripa, M.D., of the University Hospital Rigshospitalet in Copenhagen, Denmark, and colleagues conducted a randomized, double-blind study of 78 patients who had successfully undergone primary percutaneous coronary stent intervention less than 12 hours after onset of symptoms. One group of patients received G-CSF for six days while the control group received a placebo.

There was a 17 percent improvement in systolic wall thickening in both groups with comparable results in infarct border and noninfarcted myocardium. There were similar improvements in left ventricle ejection fraction and in-stent late lumen loss and target vessel revascularization rates.

The findings do not rule out the use of G-CSF in myocardial infarction patients, the authors write. "The complex interaction between stem cell mobilization and cytokines remains poorly understood, and the results do not exclude the possibility that G-CSF could be part of a treatment strategy combining several cytokines and/or local stem cell delivery in future trials."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing